LAG3 and non-small cell lung carcinoma: Interestingly, a study by Ding et al. demonstrated LAG-3 upregulation by measuring protein and mRNA in TILs from five of eight NSCLC patients with acquired resistance to checkpoint blockers, suggesting a possible role for LAG-3 in this setting [59].